Oncology Clinical Trials in Tacoma, WA
As of June 2026, 63 paid clinical trials are recruiting for Oncology in Tacoma, Washington. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
63 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
SLV-154 Treatment of Metastatic Solid Tumors
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Volrustomig Priming Regimens Exploratory Phase II Platform Study
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
About research studies in Tacoma
Tacoma has approximately 183 recruiting research studies across a wide range of therapeutic areas. Washington hosts Fred Hutchinson Cancer Center, UW Medicine, and Seattle Children's — widely recognized for leadership in bone marrow transplantation, immunotherapy, and infectious disease research.
Top Research Study Locations in Tacoma
Researchers run research studies in Tacoma, WA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Mary Bridge Children's Hospital and Health Center | Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, Ganglioneuroblastoma, Nodular | 22 |
| Franciscan Research Center-Northwest Medical Plaza | Chronic Lymphocytic Leukemia, Malignant Solid Neoplasm, Melanoma | 20 |
| Madigan Army Medical Center | Acute Myeloid Leukemia, Malignant Solid Neoplasm, Metastatic Osteosarcoma | 20 |
| Northwest Medical Specialties | Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 17 |
| Northwest Medical Specialties PLLC | Breast Cancer, Stage IIIB Lung Cancer AJCC v8, Advanced Lung Non-Squamous Non-Small Cell Carcinoma | 15 |
| Northwest Medical Specialties, PLLC | Breast Cancer Metastatic, Ovarian Cancer, Advanced Cancer | 13 |
| MultiCare Tacoma General Hospital | Anatomic Stage IV Breast Cancer AJCC v8, Breast Cancer, Cardiotoxicity | 7 |
| MultiCare Institute for Research & Innovation | Crohn's Disease, Hypogonadism, Male, Metastatic Non-small Cell Lung Cancer | 7 |
| Northwest Medical Specialties Tacoma | Chronic Lymphocytic Leukemia, Multiple Myeloma, Non Small Cell Lung Carcinoma | 6 |
| Washington Gastroenterology - Tacoma | Obesity or Overweight, Crohn's Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease | 4 |
| MultiCare Health System | Breast Neoplasms, Colitis, Ulcerative, Neoplasm Metastasis | 4 |
| Universal Research Group | Alzheimer Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Dementia | 3 |
| MultiCare Institute for Research and Innovation | Percutaneous Coronary Intervention, Peripheral Endovascular Intervention, Migraine | 3 |
| Mary Bridge Children's Health | Sickle Cell Disease, Thalassemia | 2 |
| GI Alliance Tacoma | Colitis, Ulcerative, Crohn Disease | 2 |
| GSK Investigational Site | Gastrointestinal Neoplasms, Neoplasms, Head and Neck | 2 |
| Mary Bridge Children's Hospital & Health Center | Cerebroside Lipidosis Syndrome, Gaucher Disease, Glucocerebrosidase Deficiency Disease | 2 |
| Multicare Health System - Mary Bridge Pediatrics | Developmental and Epileptic Encephalopathy, Dravet Syndrome | 2 |
| Washington Gastroenterology- GIA | Crohn's Disease, Ulcerative Colitis | 2 |
| Northwest Medical Specialties - Tacoma | Patients With Non-Small Cell Lung Cancer, Follicular Lymphoma (FL) | 2 |
| 019 | Advanced Solid Tumor | 1 |
| Anthos Investigative | Atrial Fibrillation (AF) | 1 |
| CHI Franciscan Research Center | Heart Failure, Obesity | 1 |
| Clinical Study Site | Metastatic Colorectal Cancer (CRC) | 1 |
| Clinical Trial Site | Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, Cholesterol Ester Storage Disease | 1 |
Active & Upcoming Studies in Tacoma (2026)
Recruiting trials in Tacoma grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (91 active studies)
Neurology & pain (12 active studies)
- A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy · Phase 4 · Genentech, Inc.
- A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). · Phase 3 · Eli Lilly and Company
Cardiovascular (12 active studies)
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention · Phase 4 · Duke University
Diabetes & metabolic (7 active studies)
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity · Phase 3 · Novo Nordisk A/S
- SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes · Phase 2 · SAb Biotherapeutics, Inc.
Mental health & behavior (1 active study)
- Lay-Delivered Behavioral Activation in Senior Centers · University of Washington
Pediatric (1 active study)
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine · Phase 3 · H. Lundbeck A/S
Common conditions studied in Tacoma
- Breast Cancer (8 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Multiple Myeloma (8 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Crohn's Disease (7 active studies). Recruiting Crohn's Disease studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Breast Neoplasms (5 active studies). Recruiting Breast Neoplasms studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Colitis, Ulcerative (5 active studies). Recruiting Colitis, Ulcerative studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Non-small Cell Lung Cancer (5 active studies). Lung cancer research focuses on targeted therapies for specific mutations such as EGFR, ALK, and KRAS, alongside immunotherapy regimens.
Leading research sponsors in Tacoma
- AstraZeneca
- National Cancer Institute (NCI)
- Children's Oncology Group
- AbbVie
- Eli Lilly and Company
Local regulations and guidelines
Clinical trials in Washington are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Studies in Washington must also comply with the My Health My Data Act, which adds consumer-health-data protections on top of federal HIPAA requirements.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Tacoma. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Tacoma
Hipa.ai aggregates every recruiting study in Tacoma from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Tacoma?
There are approximately 183 recruiting clinical trials in Tacoma, Washington listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Tacoma pay participants?
Most recruiting trials in Tacoma compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Tacoma?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Tacoma?
The most common conditions under active study in Tacoma include Breast Cancer (8), Multiple Myeloma (8), Crohn's Disease (7), Breast Neoplasms (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Tacoma?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Tacoma on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Tacoma?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Tacoma?
Recruiting research sites in Tacoma include Mary Bridge Children's Hospital and Health Center, Franciscan Research Center-Northwest Medical Plaza, Madigan Army Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Tacoma right now?
The largest active categories in Tacoma are Cancer & tumors (91), Neurology & pain (12), Cardiovascular (12). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.